Another Takeda/Shire R&D exec jumps ship as Pharvaris nabs Peng Lu as its new CMO

After getting off a $66 million series B round in September last year, hereditary angioedema (HAE) specialist Pharvaris has taken on a seasoned HAE developer to help lead its pipeline. The startup has nabbed former Takeda/Shire exec Peng Lu, M.D., Ph.D., as its chief medical officer; Lu comes from Shire after it has been subsumed into Japanese Big Pharma Takeda and follows a whole host of other execs who have hit the exit amid the merger. At Shire, she led the team that finished up the phase 3 pivotal HAE studies that led to the approval of Takhzyro (lanadelumab‐flyo) for the prevention of HAE attacks, which can cause life-threatening swelling of the airways or intestinal tract.